Long‐term effectiveness and safety outcomes in adults with Fabry disease treated with agalsidase alfa: 20 years of data from the Fabry Outcome Survey
European Journal of Clinical Investigation · 2026-01 · 56 (1)
DOI: 10.1111/eci.70142 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 06.11.2025. Verfasst von Derralynn A Hughes und 12 weiteren Autor:innen. Beteiligte Einrichtung: Royal Free London NHS Foundation Trust, University College London, London, UK. Hauptthemen laut MEDLINE: Fabry Disease, alpha-Galactosidase. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Development Center Americas, Inc..
Abstract (Originalsprache)
Background
We present the final report from the Fabry Outcome Survey (FOS) on long‐term effectiveness and safety of agalsidase alfa in adults (≥18 years old).
Methods
FOS was an international, multicentre, observational registry (NCT03289065), designed to enhance the understanding of Fabry disease and improve clinical management. Primary effectiveness endpoints were annualized change in estimated glomerular filtration rate (eGFR) and left ventricular mass index (LVMI), and time to and age at composite morbidity event (comprising renal, cardiac or stroke events) and death. Safety outcomes were also assessed.
Results
FOS included data for 1864 adults (female/male, n = 907/957) who received agalsidase alfa only for a median (minimum, maximum) of 6.0 (0, 21.6) years, and 1613 untreated adults (female/male, n = 1235/378). At baseline, mean (standard deviation [SD]) eGFR was 94.01 (27.60) mL/min/1.73 m 2 in treated adults; annualized changes in eGFR (slope [standard error; SE]) remained relatively stable in females and declined slightly in males (−1.07 [.12] vs. −2.17 [.12] mL/min/1.73 m 2 ). At baseline, mean (SD) LVMI was 58.25 (25.01) g/m 2.7 and LVMI (slope [SE]) remained stable (.34 [.16] vs. .38 [.15] g/m 2.7 /year in females and males, respectively). Time (median [95% confidence interval]) from treatment initiation to first composite event was longer for females than males (83.4 [65.7–98.0] vs. 56.3 [45.6–66.7] months); age (median [minimum, maximum]) at death was also higher for treated females than males (69.9 [32.5, 87.7] vs. 59.1 [26.2, 79.6] years). Agalsidase alfa was generally well tolerated.
Conclusions
This report further supports the long‐term effectiveness and safety of agalsidase alfa in adults with Fabry disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Royal Free London NHS Foundation Trust, University College London, London, UK.
- Vall d'Hebron Research Institute, Barcelona, Spain.
- Medical Consulting Committee, MPS-Lisosomales Association, Barcelona, Spain.
- Johannes Gutenberg School of Medicine, University of Mainz, Mainz, Germany.
- Takeda Pharmaceuticals International AG, Zurich, Switzerland.
- Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.
ORCID-Profile: Jaco Botha
Förderung
- Takeda Development Center Americas, Inc.
Zitieren
APA
Hughes, D. A., Pintos-Morell, G., Kampmann, C., Anagnostopoulou, C., Botha, J., Jain, S., Nicholls, K., Niu, D. M., Reisin, R., West, M. L., Schenk, J., Ramaswami, U., & Giugliani, R. (2026). Long‐term effectiveness and safety outcomes in adults with Fabry disease treated with agalsidase alfa: 20 years of data from the Fabry Outcome Survey. European Journal of Clinical Investigation, 56(1). https://doi.org/10.1111/eci.70142
Vancouver
Hughes DA, Pintos-Morell G, Kampmann C, Anagnostopoulou C, Botha J, Jain S, et al. Long‐term effectiveness and safety outcomes in adults with Fabry disease treated with agalsidase alfa: 20 years of data from the Fabry Outcome Survey. European Journal of Clinical Investigation. 2026;56(1). doi:10.1111/eci.70142
BibTeX
@article{Hughes2026,
author = {Hughes, Derralynn A and Pintos-Morell, Guillem and Kampmann, Christoph and Anagnostopoulou, Christina and Botha, Jaco and Jain, Siddharth and Nicholls, Kathleen and Niu, Dau-Ming and Reisin, Ricardo and West, Michael L and Schenk, Jörn and Ramaswami, Uma and Giugliani, Roberto},
title = {Long‐term effectiveness and safety outcomes in adults with Fabry disease treated with agalsidase alfa: 20 years of data from the Fabry Outcome Survey},
journal = {European Journal of Clinical Investigation},
year = {2026},
volume = {56},
number = {1},
doi = {10.1111/eci.70142}
}
EUVIMED